IDEXX LABORATORIES INC /DE

IDXXSEC EDGAR

In Vitro & In Vivo Diagnostic Substances(DE)CIK: 874716

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$3.7B	$3.4B	$3.2B	$2.7B	$2.4B
Cost of Goods and Services Sold	$1.5B	$1.4B	—	—	—
Gross Profit	$2.2B	$2.0B	$1.9B	$1.6B	$1.4B
Research and Development Expense	$191.0M	$254.8M	$161.0M	$141.2M	$133.2M
Operating Expenses	$1.1B	$1.1B	—	—	—
Operating Income (Loss)	$1.1B	$898.8M	$932.0M	$694.5M	$552.8M
Interest Expense	—	—	$29.8M	$33.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$3.3B	$3.3B	$2.7B	$2.4B	$2.3B
Assets, Current	$1.4B	$1.5B	$1.1B	$955.7M	$1.1B
Cash and Cash Equivalents, at Carrying Value	$288.3M	$453.9M	$112.5M	$144.5M	$383.9M
Accounts Receivable, after Allowance for Credit Loss, Current	$473.6M	$457.4M	$400.6M	$368.3M	$331.4M
Inventory, Net	$381.9M	$380.3M	$367.8M	$269.0M	$209.9M
Liabilities	$1.7B	$1.8B	$2.1B	$1.7B	$1.7B
Liabilities, Current	$1.1B	$951.5M	$1.2B	$763.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$906.5M	$543.0M	$755.5M	$648.1M	$459.2M
Net Cash Provided by (Used in) Investing Activities	-$125.3M	-$195.3M	-$293.0M	-$109.4M	-$205.5M
Net Cash Provided by (Used in) Financing Activities	-$442.0M	-$370.9M	-$697.4M	-$248.4M	-$286.4M
Payments to Acquire Property, Plant, and Equipment	$133.6M	$148.8M	$119.5M	$107.0M	$155.0M
Payments for Repurchase of Common Stock	$71.9M	$819.7M	$746.8M	$182.8M	$301.7M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)